Trial Profile
Effect of the Administration of the Combination of Dapagliflozin Plus Metformin XR Versus Monotherapies on Anthropometric Indicators in Patients With Grade 1 Obesity
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Dapagliflozin/metformin (Primary) ; Metformin (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 22 May 2023 Planned End Date changed from 30 Nov 2022 to 30 Dec 2023.
- 22 May 2023 Planned primary completion date changed from 30 Jul 2022 to 30 Dec 2023.
- 02 Jun 2022 Planned End Date changed from 30 Nov 2021 to 30 Nov 2022.